Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Nov 2017
Price : $35 *
At a glance
- Drugs Pralatrexate (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Mundipharma International
- 01 Oct 2017 Results assessing the efficacy of pralatrexate in patients with T-cell lymphoma, were published in the Cancer Science.
- 01 Oct 2017 Status changed from active, no longer recruiting to completed, according to results published in the Cancer Science.
- 03 Aug 2017 Planned End Date changed from 1 Dec 2015 to NULL.